TW201902489A - 核酸寡核苷酸與核苷類似物化學治療劑之協同性組合 - Google Patents

核酸寡核苷酸與核苷類似物化學治療劑之協同性組合 Download PDF

Info

Publication number
TW201902489A
TW201902489A TW107111859A TW107111859A TW201902489A TW 201902489 A TW201902489 A TW 201902489A TW 107111859 A TW107111859 A TW 107111859A TW 107111859 A TW107111859 A TW 107111859A TW 201902489 A TW201902489 A TW 201902489A
Authority
TW
Taiwan
Prior art keywords
sirna
nucleic acid
madd
cancer
shrna
Prior art date
Application number
TW107111859A
Other languages
English (en)
Chinese (zh)
Inventor
貝勒 帕拉哈卡
希妮 霍普斯
艾帝堤 麥瑟
岳菲
席哈 賽尼
Original Assignee
美商吉瓦納生技公司
伊利諾大學董事會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商吉瓦納生技公司, 伊利諾大學董事會 filed Critical 美商吉瓦納生技公司
Publication of TW201902489A publication Critical patent/TW201902489A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW107111859A 2017-04-24 2018-04-03 核酸寡核苷酸與核苷類似物化學治療劑之協同性組合 TW201902489A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762489061P 2017-04-24 2017-04-24
US62/489,061 2017-04-24

Publications (1)

Publication Number Publication Date
TW201902489A true TW201902489A (zh) 2019-01-16

Family

ID=63919871

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107111859A TW201902489A (zh) 2017-04-24 2018-04-03 核酸寡核苷酸與核苷類似物化學治療劑之協同性組合

Country Status (3)

Country Link
AR (1) AR111408A1 (fr)
TW (1) TW201902489A (fr)
WO (1) WO2018200145A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007084954A2 (fr) * 2006-01-19 2007-07-26 The Board Of Trustees Of The University Of Illinois Inhibition sélective des variantes d'épissure de l'ig20 pour traiter le cancer

Also Published As

Publication number Publication date
AR111408A1 (es) 2019-07-10
WO2018200145A1 (fr) 2018-11-01

Similar Documents

Publication Publication Date Title
JP6730285B2 (ja) Ｒｎａ干渉組成物及び悪性腫瘍のための方法
JP2022008404A (ja) Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物
US7858592B2 (en) Interfering RNAs against the promoter region of P53
AU2016251415B2 (en) C/EBP alpha saRNA compositions and methods of use
KR20090019790A (ko) 단백질 미스폴딩의 치료
US20130237584A1 (en) CANCER THERAPY USING Bcl-XL-SPECIFIC siNA
US20130018086A1 (en) Sirnas targeting exon 10 of pyruvate kinase m2
US12012597B2 (en) Cancer treatment using siRNA to modulate expression of PRDM2/RIZ protein
JP5397692B2 (ja) 悪性黒色腫抗原の発現上昇剤及びその用途
TW201902489A (zh) 核酸寡核苷酸與核苷類似物化學治療劑之協同性組合
TW201902910A (zh) 核酸寡核苷酸與細胞凋亡誘導性分子治療劑之協同增效性組合
US11273172B2 (en) Synergistic combination of oligonucleotides and chemotherapeutic for treating cancer
WO2005089800A1 (fr) COMPOSITION PHARMACEUTIQUE CONTENANT DE LA hsHRD3
TW201902487A (zh) 核酸寡核苷酸與蛋白質激酶抑制劑化學療法的協同性組合
TW201900183A (zh) 核酸寡核苷酸與烷化劑化學治療劑之協同增效性組合
TW201902488A (zh) 核酸寡核苷酸與紫杉烷化學治療劑之協同增效性組合
TW201902912A (zh) 核酸寡核苷酸及蒽環化學療劑之協同性組合
KR101414383B1 (ko) Ｄｌｋ-1 유전자 발현억제용 조성물
WO2011036879A1 (fr) Préparation de liposome de transferrine
WO2007088900A1 (fr) Arn double brin induisant la mort cellulaire